LATEST TRIALS

  • Multiple Diagnosis
    A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS
  • Solide Tumores
    A first-in-human, multicenter, open-label, phase 1 study in patients with advanced and/or refractory
  • Solide Tumores
    A phase Ia/Ib, first-in-human, open label, multicentre, dose-escalation and dose-expansion study of a novel NanoZolid®-docetaxel depot formulation (NZ-DTX Depot) given as an intra-tumoural injection in patients with advanced solid tumours

NORDIC COOPERATION

Norway Norway Sweden Finland Finland Finland Aarhus Herlev Copenhagen Copenhagen Lund